
A study of 84 patients aged 21 or younger has found that colorectal cancer in young patients is frequently diagnosed only after it has reached Stage III or IV, raising questions about whether warning signs are being taken seriously enough in younger age groups. The findings were presented at the American Academy of Pediatrics 2026 National Conference & Exhibition, held 2-6 October 2026 at the San Diego Convention Center.
The study, titled ‘Clinical Presentation and Epidemiology of Pediatric and Adolescent Colorectal Carcinoma: A Pediatric Surgical Oncology Research Collaborative Study,’ reviewed medical records from patients diagnosed with colorectal cancer between 2012 and 2023. The majority already had advanced-stage disease by the time they received a diagnosis.
What the study found about colorectal cancer in young patients
One figure stands out: only 20% of those in the study had a first- or second-degree family history of colorectal cancer. Yet most presented with aggressive, late-stage disease regardless. That combination, low family-history rates alongside high rates of advanced presentation, is what the researchers say makes this population difficult to manage and easy to overlook.
According to EurekAlert!, the study excluded patients who had a known colorectal cancer predisposition syndrome before diagnosis, including those with genetic syndromes or inflammatory bowel disease. That exclusion matters. It means the cohort does not represent patients who might be expected to be under closer surveillance. These were, by and large, patients without the obvious prior risk flags, which makes the prevalence of late-stage disease at diagnosis harder to explain away.
Possible warning signs listed by the researchers include lower back pain, abdominal pain, changes in bowel habits, unexplained weight loss, and rectal bleeding. Because colorectal cancer remains uncommon in younger patients, these symptoms may not immediately raise clinical suspicion and can be attributed to more routine causes.
Aggressive disease and poor outcomes
‘Colorectal cancer is, unfortunately, becoming more common in adolescents and young adults and represents a different disease than colorectal cancer diagnosed in older adults,’ said Erica Arnold, MD, study author and pediatric surgery research fellow. ‘When diagnosed, it is often aggressive, presenting with late-stage disease and associated with high rates of disease relapse and mortality.’
The outcome data in the study are sobering. More than one-third of the patients subsequently developed recurrent disease. Nearly half died as a result of their diagnosis. The researchers attribute those figures to a combination of delayed diagnosis and the inherently aggressive behaviour of tumours presenting in younger patients. These are not outcomes driven by treatment failure alone; they reflect how far the disease had progressed before it was found.
Delays in diagnosis, the authors argue, are at least partially avoidable. The symptoms, while non-specific, are not invisible. Rectal bleeding and unexplained weight loss, in particular, are symptoms that the researchers say should prompt serious investigation even when the patient is young. The clinical tendency to anchor on more probable diagnoses in adolescents and young adults may be contributing to the pattern the study describes.
Coordination between paediatric and adult teams
The researchers also highlight a structural problem. Colorectal cancer in adults is managed within well-established oncology pathways. In younger patients, it falls into a more uncertain space between paediatric and adult medicine. The authors stress the importance of co-ordinating care between paediatric and adult medical teams, and of developing treatment protocols specifically tailored to this age group rather than adapting adult plans.
That call for joined-up care reflects the wider pattern the study describes: a disease that belongs neither cleanly to paediatrics nor to adult oncology, presenting in patients who were not expected to develop it, at a stage when the options are already limited.
The full study was presented at the American Academy of Pediatrics conference as part of a broader body of work through the Pediatric Surgical Oncology Research Collaborative. Further details of the research are available via ScienceDaily.



